相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)
Vivian A. Fonseca et al.
DIABETES CARE (2012)
Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)
Y. Seino et al.
DIABETES OBESITY & METABOLISM (2012)
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Juris J. Meier
NATURE REVIEWS ENDOCRINOLOGY (2012)
Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans
Michael A. Nauck et al.
DIABETES (2011)
Comment on: American Diabetes Association. Standards of medical care in diabetes-2011 (vol 34, pg e53, 2011)
V Basevi et al.
DIABETES CARE (2011)
Contributions of Basal and Postprandial Hyperglycemia Over a Wide Range of A1C Levels Before and After Treatment Intensification in Type 2 Diabetes
Matthew Riddle et al.
DIABETES CARE (2011)
The role of dysregulated glucagon secretion in type 2 diabetes
D. D'Alessio
DIABETES OBESITY & METABOLISM (2011)
An overview of once-weekly glucagon-like peptide-1 receptor agonists-available efficacy and safety data and perspectives for the future
S. Madsbad et al.
DIABETES OBESITY & METABOLISM (2011)
The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review
Vanita R. Aroda et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2011)
Lixisenatide for type 2 diabetes mellitus
Mikkel Christensen et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
Effect of Exenatide on Splanchnic and Peripheral Glucose Metabolism in Type 2 Diabetic Subjects
E. Cersosimo et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Standards of Medical Care in Diabetes-2011 AMERICAN DIABETES ASSOCIATION
DIABETES CARE (2011)
The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action
Kristine J. Hare et al.
DIABETES (2010)
Patient-reported tolerability issues with oral antidiabetic agents: Associations with adherence; treatment satisfaction and health-related quality of life
Michael F. Pollack et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2010)
Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial
R. E. Ratner et al.
DIABETIC MEDICINE (2010)
Population Pharmacokinetics of Liraglutide, a Once-Daily Human Glucagon-Like Peptide-1 Analog, in Healthy Volunteers and Subjects With Type 2 Diabetes, and Comparison to Twice-Daily Exenatide
Estelle Watson et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
Michaela Diamant et al.
LANCET (2010)
Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes
Ulrich Werner et al.
REGULATORY PEPTIDES (2010)
Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) - preclinical and clinical results
Sten Madsbad
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
Michael Nauck et al.
DIABETES CARE (2009)
Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
Bernard Zinman et al.
DIABETES CARE (2009)
Relative and absolute contributions of postprandial and fasting plasma glucose to daytime hyperglycaemia and HbA1c in subjects with Type 2 diabetes
R. Peter et al.
DIABETIC MEDICINE (2009)
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
M. Marre et al.
DIABETIC MEDICINE (2009)
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
D. Russell-Jones et al.
DIABETOLOGIA (2009)
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
Alan Garber et al.
LANCET (2009)
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
John B. Buse et al.
LANCET (2009)
Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes
Antonio Cervera et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2008)
International Diabetes Federation guideline for management of postmeal glucose: a review of recommendations
A. Ceriello et al.
DIABETIC MEDICINE (2008)
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
Daniel J. Drucker et al.
LANCET (2008)
Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
Helle Linnebjerg et al.
REGULATORY PEPTIDES (2008)
Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes -: Importance of postprandial glycemia to achieve target HbA1c levels
Hans J. Woerle et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2007)
The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes
Louis Monnier et al.
DIABETES CARE (2007)
Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus
K Esposito et al.
CIRCULATION (2004)
Synthetic exendin-4 (Exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes
OG Kolterman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients -: Variations with increasing levels of HbA1c
L Monnier et al.
DIABETES CARE (2003)
Morning hyperglycemic excursions - A constant failure in the metabolic control of non-insulin-using patients with type 2 diabetes
L Monnier et al.
DIABETES CARE (2002)
The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men
H Agerso et al.
DIABETOLOGIA (2002)
分享论文
